Yellow Fever Clinical Presentation

  • Author: Mary T Busowski, MD; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Sep 15, 2011
 

History

To arrive at a diagnosis, consider the patient's clinical features and his or her places and dates of travel, including the epidemiologic history of the places visited, immunizations, and activities.

After an incubation period of 3-6 days, most individuals with yellow fever have a mild, self-limiting illness consisting of fever, headache, myalgia, and malaise. More serious illness develops in 15% of cases and presents with the abrupt onset of general malaise, fever, chills, headache, lower back pain, nausea, and dizziness. Physical findings include pulse-fever dissociation (Faget sign), conjunctival injection, and facial flushing.

Significant laboratory findings usually include leukopenia with relative neutropenia. Transaminase levels may rise 48-72 hours after initial symptoms appear. This is followed by a period of remission, with normalization of symptoms and temperature for up to 24 hours. The patient may then either recover or progress to fatal illness (up to half of cases).

Remission followed by the return of symptoms is classified as the period of intoxication. Viremia is reduced, and humoral-mediated reactions are responsible for marked physical illness.[9] This stage is marked by fever, vomiting, abdominal pain, renal failure, and hemorrhage. Petechiae, ecchymoses, epistaxis, and bleeding from gums and venipuncture sites can progress to melena, hematemesis, and metrorrhagia.

Jaundice worsens as the levels of transaminases increase, with serum aspartate aminotransferase (AST) levels typically higher than those of alanine aminotransferase (ALT) owing to direct viral injury to skeletal muscle tissue and myocardium. Progressive liver involvement and humoral-mediated responses can lead to consumption coagulopathy. Prolonged clotting and prothrombin times and reduced levels of fibrinogen and clotting factors II, V, VII, VIII, IX, X occur; also, fibrin split products appear.

Hepatorenal disease carries a mortality rate of 20%-50%; with death occurring 7-10 days after onset of symptoms. The terminal phase is marked by delirium, stupor, and coma due to cerebral edema and microscopic perivascular hemorrhage.

Next

Physical Examination

Physical examination findings for yellow fever include fever, relative bradycardia for the degree of fever (Faget sign), conjunctival injection, and skin flushing.

Other physical findings, such as scleral icterus, jaundice, epigastric tenderness, and hepatomegaly, develop as disease progresses. Early appearance of jaundice indicates a poor prognosis.

Disseminated intravascular coagulation (DIC), induced by liver dysfunction, leads to consumption of platelets and clotting factors. This process clinically presents as a combination of a bleeding diathesis and organ ischemia secondary to fibrin deposition throughout the microcirculation. Petechiae, purpura, mucosal bleeding, and gastrointestinal bleeding (gross or hemoccult) will often be apparent.

Ischemia primarily affects the kidneys and central nervous system leading to altered mental status and/or signs of volume overload (jugular venous distension, presence of rales, and S3 gallop, or edema).

Late stages

In late stages of disease, shock and multiorgan dysfunction syndrome (MODS) dominate the clinical picture. These septic patients present with tachycardia, hypothermia or hyperthermia, and hypotension. Individuals who are severely hypoperfused appear mottled and cyanotic. They are also often obtunded.

Tachypnea and hypoxia with impending respiratory failure may develop as a consequence of sepsis and acute respiratory distress syndrome (ARDS).

Previous
 
 
Contributor Information and Disclosures
Author

Mary T Busowski, MD  Infectious Disease Faculty Practice/Internal Medicine Faculty Practice, Orlando Health; Clinical Instructor of Medicine, Florida State University School of Medicine

Mary T Busowski, MD, is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American College of Physicians, American Medical Association, Florida Medical Association, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Coauthor(s)

Dan Danzl, MD  Chair, Professor, Department of Emergency Medicine, University of Louisville Hospital

Dan Danzl, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Kentucky Medical Association, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Aleksandr Gleyzer, MD, FAAEM  Assistant Professor, Department of Emergency Medicine, State University of New York Downstate Medical Center; Attending Physician, Department of Emergency Medicine, Kings County Medical Center and Brooklyn Veterans Affairs Medical Center

Aleksandr Gleyzer, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine and International Society of Travel Medicine

Disclosure: Nothing to disclose.

Emily Nichols, MD  Clinical Assistant Instructor, State University of New York Downstate Medical Center, Kings County Hospital Center

Emily Nichols, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Emergency Medicine Residents Association, and National Medical Association

Disclosure: Nothing to disclose.

Janelle L Robertson, MD  Staff Physician, Department of Infectious Diseases, Wilford Hall Medical Center

Janelle L Robertson, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Mark R Wallace, MD, FACP, FIDSA  Clinical Professor of Medicine, Florida State University College of Medicine; Head of Infectious Disease Fellowship Program, Orlando Regional Medical Center

Mark R Wallace, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Tropical Medicine and Hygiene, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Specialty Editor Board

Thomas E Herchline, MD  Professor of Medicine, Wright State University, Boonshoft School of Medicine; Medical Director, Public Health, Dayton and Montgomery County, Ohio

Thomas E Herchline, MD is a member of the following medical societies: Alpha Omega Alpha, Infectious Diseases Society of America, and Infectious Diseases Society of Ohio

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Richard B Brown, MD, FACP  Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine

Richard B Brown, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Mark L Plaster, MD, JD  Executive Editor, Emergency Physicians Monthly

Mark L Plaster, MD, JD is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians

Disclosure: M L Plaster Publishing Co LLC Ownership interest Management position

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of Medscape Reference gratefully acknowledge the medical review of the source article by Joseph U Becker, MD.

References
  1. Bob Arnebeck. A Short History of Yellow Fever in the US. Available at http://www.geocities.com/bobarnebeck/history.html. Accessed November 11, 2008.

  2. Kean BH, Dahlby T. Coming of age in Panama. In: One Doctor's Adventures Among the Famous and Infamous from the Jungles of Panama to a Park Avenue Practice. New York, NY: Ballantine Books; 1990:Ch 2.

  3. Bryan CS, Moss SW, Kahn RJ. Yellow fever in the Americas. Infect Dis Clin North Am. 2004;18:275-279.

  4. Cleri DJ, Ricketti AJ, Porwancher RB, Ramos-Bonner LS, Vernaleo JR. Viral hemorrhagic fevers: current status of endemic disease and strategies for control. Infect Dis Clin North Am. Jun 2006;20(2):359-93, x. [Medline].

  5. Roukens AH, Visser LG. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther. Nov 2008;8(11):1787-95. [Medline].

  6. Bhatiasevi A, Moen C. More funding urged for yellow fever vaccine stockpile. WHO News Releases 2009. Available at http://www.who.int/mediacentre/news/releases/2009/yellow_fever_vaccine_20090526/en/index.html. Accessed May 31, 2009.

  7. Tsai TF, Vaughn DW, Solomon T. Flaviviruses. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol 2. 6th ed. Philadelphia, Pennsylvania: Elsevier, Inc.; 2005:Ch 149; 1926-9.

  8. World Health Organization. Yellow fever factsheet (revised in December 2009). Weekly Epidemiological Record. Jan 2010.

  9. Barrett AD, Higgs S. Yellow fever: A disease that has yet to be conquered. Annu Rev Entomol. 2007;52:209-229.

  10. Monath TP. Treatment of yellow fever. Antiviral Res. Apr 2008;78(1):116-24. [Medline].

  11. Barnett ED, Wilder-Smith A, Wilson ME. Yellow fever vaccines and international travelers. Expert Rev Vaccines. Jul 2008;7(5):579-87. [Medline].

  12. Centers for Disease Control and Prevention. Fatal Yellow Fever in a Traveler Returning from Venezula, 1999. CDC. Apr 14 2000;49(14):303-5. Accessed Aug 16 2011. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4914a3.htm.

  13. Darsie RF, Ward RA. Gainesville FL. Identification and Geographical Distribution of the Mosquitoes of North America. University of Florida Press; 2005.

  14. Morens DM, Fauci AS. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA. Jan 9 2008;299(2):214-6. [Medline].

  15. Kim DY, Guzman H, Bueno R Jr, et al. Characterization of Culex Flavivirus (Flaviviridae) strains isolated from mosquitoes in the United States and Trinidad. Virology. Mar 30 2009;386(1):154-9. [Medline].

  16. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. Mar 15 2007;44(6):850-6. [Medline].

  17. World Health Organization. Media centre fact sheets: Yellow fever. Updated December 2001. World Health Organization. Available at http://www.who.int/mediacentre/factsheets/fs100/en/. Accessed May 13, 2009.

  18. Centers for Disease Control and Prevention. Traveler's Health. CDC. Available at http://wwwnc.cdc.gov/travel. Accessed Aug 16 2011.

  19. World Health Organization. WHO position paper: Yellow fever vaccine. Geneva, Switzerland: Oct 2003. Weekly Epidemiological Record; [Full Text].

  20. World Health Organization. Update on progress controlling yellow fever in Africa, 2004-2008. Geneva, Switzerland: Dec 2008. Weekly Epidemiological Record.

  21. Receveur MC, Bruyand M, Pistone T, Malvy D. Yellow fever vaccination: Update on rare and severe adverse effects. Médecine et Maladies Infectieuses. 2009;39:239-241.

  22. Julander JG, Furuta Y, Shafer K, Sidwell RW. Activity of T-1106 in a hamster model of yellow Fever virus infection. Antimicrob Agents Chemother. Jun 2007;51(6):1962-6. [Medline]. [Full Text].

  23. Bruyand M, Receveur MC, Pistone T, Verdière CH, Thiebaut R, Malvy D. [Yellow fever vaccination in non-immunocompetent patients]. Med Mal Infect. Oct 2008;38(10):524-32. [Medline].

Previous
Next
 
Yellow fever virus. Image courtesy of the Centers for Disease Control and Prevention.
This female Aedes aegypti mosquito is shown after landing on a human host. The A aegypti mosquito is a known transmitter of dengue fever and yellow fever. A aegypti is sometimes referred to as the yellow fever mosquito. The viruses are transferred to the host when he or she has been bitten by a female mosquito. Image courtesy of the CDC/World Health Organization (WHO).
Global distribution of yellow fever. Image courtesy of the Centers for Disease Control and Prevention.
Transmission cycles of yellow fever in Africa and South America. Adapted from Annu Rev Entomol. 2007. 52:209-29.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.